A5026803534- Renal cell carcinoma treatment
- Cancer Immunotherapy and Biomarkers
- Renal and related cancers
- Prostate Cancer Treatment and Research
- Bladder and Urothelial Cancer Treatments
- Economic and Financial Impacts of Cancer
- Cancer Genomics and Diagnostics
- Cancer Diagnosis and Treatment
- Sarcoma Diagnosis and Treatment
- Hormonal and reproductive studies
- Pancreatic and Hepatic Oncology Research
- Brain Metastases and Treatment
- Cancer Treatment and Pharmacology
- T-cell and B-cell Immunology
- Head and Neck Cancer Studies
- Immune Cell Function and Interaction
- Immunotherapy and Immune Responses
- Medical Imaging and Pathology Studies
- Lung Cancer Treatments and Mutations
- CAR-T cell therapy research
- Gastrointestinal Tumor Research and Treatment
- Urinary and Genital Oncology Studies
- Radiopharmaceutical Chemistry and Applications
- Tuberous Sclerosis Complex Research
- Health Systems, Economic Evaluations, Quality of Life
Medizinische Hochschule Hannover
2016-2025
German Cancer Society
2021-2025
Heidelberg University
2024
University Hospital Heidelberg
2024
National Center for Tumor Diseases
2024
Hochschule Hannover
2022-2024
STZ eyetrial
2022
PURPOSE The anti-NECTIN4 antibody-drug conjugate enfortumab vedotin (EV) is approved for patients with metastatic urothelial cancer (mUC). However, durable benefit only achieved in a small, yet uncharacterized patient subset. NECTIN4 located on chromosome 1q23.3, and 1q23.3 gains represent frequent copy number variations (CNVs) cancer. Here, we aimed to evaluate amplifications as genomic biomarker predict EV response mUC. MATERIALS AND METHODS We established NECTIN4-specific fluorescence...
PURPOSE Doxorubicin is a standard of care in patients with advanced, inoperable soft tissue sarcoma (STS). We tested whether pazopanib has efficacy comparable to that doxorubicin elderly STS and offers superior tolerability for hematologic toxicity. PATIENTS AND METHODS Patients age 60 years or older without previous systemic treatment progressive advanced metastatic who had Eastern Cooperative Oncology Group performance status 0 2 adequate organ function were included. Treatment consisted...
Treatment options for patients with urothelial cancer (UC) refractory to platinum and immunotherapy are limited survival is short. Enfortumab vedotin (EV) a monoclonal anti-NECTIN4 antibody conjugated monomethyl auristatin. It was recently approved because of superior in comparison standard-of-care (SOC) chemotherapy. Real-world patients, however, often have worse characteristics than included clinical trials.To analyze the efficacy safety EV cohort real-world patients.Retrospective data...
673 Background: The anti-NECTIN4 antibody-drug conjugate (ADC) enfortumab vedotin (EV) is approved for patients with metastatic urothelial cancer (mUC). However, durable benefit only achieved in a small, yet uncharacterized patient subset. NECTIN4 located on chromosome 1q23.3, and 1q23.3 gains are frequent genomic events mUC leading to amplifications. Here, we aimed evaluate the potential of amplification as biomarker predict EV response mUC. Methods: We established NECTIN4-specific...
Chronic lung allograft dysfunction (CLAD) remains the leading cause of mortality in transplant recipients after first year. Treatment limited and unpredictable. Existing data suggests extracorporeal photopheresis (ECP) may be beneficial. This study aimed to identify factors predicting treatment response prognostic implications. A single center retrospective analysis all patients commencing ECP for CLAD between November 1, 2007 September 2011 was performed. In total 65 were included, 64 whom...
Hepatocellular carcinoma (HCC) is one of the most lethal cancers. Nutrition- and life style-associated risk factors are increasingly prevalent. Metformin, mainstay type 2 diabetes mellitus (T2DM)-treatment, reduces hepatocarcinogenesis. However, its influence on prognosis patients with HCC has not been investigated a large scale, yet.Five thousand ninety-three treated for between 2000 2016 at three referral centres were included in this retrospective multicentre study. The aim study was to...
Abstract Background Oncological patients can benefit substantially from treatment with immune checkpoint inhibitors (ICI). However, there is a growing awareness of immune‐related adverse events (irAE). Especially ICI‐mediated neurological (nAE(+)), are tough to diagnose and biomarkers identify at risk missing. Methods A prospective register prespecified examinations was established for ICI treated in December 2019. At the time data cut‐off, 110 were enrolled completed clinical protocol....
Abstract Background Tyrosine kinase inhibitors (TKI) have enriched the therapeutic options in patients with renal cell carcinoma (RCC), which frequently induce morphological changes tumors. However, only little is known about biological activity of TKI. Circulating endothelial cells (CEC) been associated damage and, hence, may serve as a putative marker for The main objective our study was to evaluate predictive value CEC, monocytes, and soluble vascular growth factor receptor (sVEGFR)-2 RCC...
Abstract Purpose The management of soft tissue sarcoma (STS) at reference centers with specialized multidisciplinary tumor boards (MTB) improves patient survival. German Cancer Society (DKG) certifies in German-speaking countries, promoting high standards care. This study investigated the variability treatment recommendations for localized STS across different tertiary centers. Methods In this cross-sectional case-based survey study, 5 anonymized cases imaging data were presented to MTBs 21...
Abstract Although osteosarcomas are the most frequent primary malignant bone tumors, cranial manifestation of this condition is very rare with only a limited number cases presented in literature. We present case 20-year-old male patient who underwent single-session surgical intervention for resection right frontal osteosarcoma tailor-made craniotomy and cranioplasty using virtually designed 3D-printed templates molds. Subsequently, was treated according to EURAMOS protocol received adjuvant...
ABSTRACT Introduction Immune checkpoint inhibitors (ICI) have improved the therapeutic arsenal in outpatient oncology care; however, data on necessity of hospitalizations associated with immune‐related adverse events (irAEs) are scarce. Here, we characterized patients undergoing ICI, from prospective cohort study immune cooperative group (ICOG) Hannover. Methods Between 12/2019 and 06/2022, 237 were included. Clinical characteristics ICI collected during a 6‐month observation period after...
474 Background: In the JAVELIN Renal 101 phase 3 trial, 1L avelumab + axitinib resulted in significantly longer progression-free survival (PFS) and a higher objective response rate (ORR) vs sunitinib patients with aRCC, an acceptable safety profile. The AVION study is evaluating effectiveness of routine clinical practice various countries. We report data from primary analysis. Methods: prospective noninterventional aRCC receiving Germany, Greece, Belgium, or Russia. Patients are observed for...
523 Background: Tyrosine kinase (TKI) and immune checkpoint inhibitors (CPI) are first-line options in metastatic renal cell carcinoma (mRCC). Most patients (pts) experience adverse events (AE) 20-30% discontinue therapies due to AEs. We tested whether proactive onco-coaching (POC) improved quality of life (QoL) with medical treatment. Methods: Adult treatment-naïve mRCC pts who were candidates for sunitinib (SU), axitinib + avelumab (AA) or pembrolizumab (AP) eligible. Treatment...
488 Background: Chromophobe (chRCC) renal cell carcinoma are rare cancers and obtain a worse prognosis. We evaluated real-world treatment outcomes of 1 st line in these cohort Germany. Methods: retrospectively analyzed patients with metastatic chRCC treated at 17 German tertiary cancer centres being from 2008-2023. Adverse events (AE) were reported according to CTCAE 5.0, objective response rate (ORR) local standard radiological clinical judgement. Progression free survival (PFS) overall...
498 Background: IO-based combination therapies - either in with tyrosine kinase inhibitors (TKI) or as double checkpoint inhibition have revolutionized first-line treatment of ccRCC patients. We compared tolerability and effectiveness ipilimumab plus nivolumab (ipi/nivo), cabozantinib (cabo/nivo), axitinib pembrolizumab (axi/pem), lenvatinib (len/pem) real-world cohorts. Methods: Data from retrospective, multicenter cohorts advanced patients were analyzed. Best response was evaluated by...
496 Background: Papillary (pRCC) renal cell carcinoma is a rare cancer. We evaluated real-world treatment outcomes of 1st line in these cohorts Germany. Methods: Data were collected retrospectively from 13 GU cancer centres Patients (pts) with advanced or metastatic pRCC eligible. Adverse events (AEs) reported according to CTCAE 5.0. ORR was accessed local standard. Progression Free Survival (PFS) calculated start progression death. Descriptive statistics and KM-plots utilized, where...